Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML0P72)

• Drug Name: O-arachidonoyl ethanolamine Drug Info
• Synonyms: Virodhamine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5712057
  CAS Number: CAS 287937-12-6
  TTD Drug ID: DML0P72

Molecule-Related Drug Atlas

Drug(s) Targeting G-protein coupled receptor 55 (GPR55)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]
BIO-017	DMYHK3Y	Angelman syndrome	LD90.0	Phase 1	[3]
N-oleoylethanolamide	DMJQ4L7	Discovery agent	N.A.	Investigative	[1]
[3H]CP55940	DMU7FC5	Discovery agent	N.A.	Investigative	[1]
lysophosphatidylinositol	DMETM3R	Discovery agent	N.A.	Investigative	[4]
O-1602	DM9VISB	Discovery agent	N.A.	Investigative	[5]
abnormal cannabidiol	DMV6DAO	Discovery agent	N.A.	Investigative	[1]
CID1172084	DMK6YOP	Discovery agent	N.A.	Investigative	[6]
CID16020046	DMLWZRT	Discovery agent	N.A.	Investigative	[7]
2-arachidonyl glyceryl ether	DM2H8TV	Discovery agent	N.A.	Investigative	[1]

Drug(s) Affected By Cannabinoid receptor 1 (CNR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[8]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[9]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[11]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[12]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[13]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[14]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[15]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[16]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[17]

Drug(s) Affected By Cannabinoid receptor 2 (CNR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[18]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[19]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[20]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[21]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[22]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[12]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[16]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[24]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
G-protein coupled receptor 55 (GPR55)	TTNET8J	GPR55_HUMAN	Agonist	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cannabinoid receptor 1 (CNR1)	OTEALO6G	CNR1_HUMAN	Gene/Protein Processing	[2]
Cannabinoid receptor 2 (CNR2)	OTYP9P43	CNR2_HUMAN	Gene/Protein Processing	[2]

References

• [1] The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
• [2] (Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jul;380(1):67-77. doi: 10.1007/s00210-009-0406-z. Epub 2009 Mar 3.
• [3] Clinical pipeline report, company report or official report of Biom Therapeutics
• [4] Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
• [5] International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev. 2010 Dec;62(4):588-631.
• [6] Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47.
• [7] A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther. 2013 Jul;346(1):54-66.
• [8] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [9] Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol Med. 2011;17(11-12):1285-94. doi: 10.2119/molmed.2011.00149. Epub 2011 Aug 19.
• [10] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [11] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [12] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [13] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [14] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [15] Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue. Diabetes. 2018 Jul;67(7):1226-1236. doi: 10.2337/db17-1366. Epub 2018 Apr 12.
• [16] Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. Neuroimmunomodulation. 2012;19(3):180-6. doi: 10.1159/000331474. Epub 2012 Jan 18.
• [17] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [18] Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem. 2000 Jan 7;275(1):605-12. doi: 10.1074/jbc.275.1.605.
• [19] Cloning and pharmacological characterization of the dog cannabinoid CB?receptor. Eur J Pharmacol. 2011 Nov 1;669(1-3):24-31. doi: 10.1016/j.ejphar.2011.08.002. Epub 2011 Aug 19.
• [20] hiPSC-Based Model of Prenatal Exposure to Cannabinoids: Effect on Neuronal Differentiation. Front Mol Neurosci. 2020 Jul 6;13:119. doi: 10.3389/fnmol.2020.00119. eCollection 2020.
• [21] Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
• [22] Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
• [23] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [24] Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011 Apr 28;2(4):e152. doi: 10.1038/cddis.2011.36.
• [25] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.